-+ 0.00%
-+ 0.00%
-+ 0.00%

Hutchmed (China) Starts Phase 3 Trial of Combination Pancreatic Cancer Treatment

MT Newswires·01/04/2026 23:18:01
Listen to the news
11:18 PM EST, 01/04/2026 (MT Newswires) -- Hutchmed (China) (HCM.L) said Monday it started the third phase of the efficacy study for the combination of surufatinib, camrelizumab, nab-paclitaxel and gemcitabine as a first-line treatment in China for adults with metastatic pancreatic ductal adenocarcinoma. The trial compares the efficacy of the combination formulation against a treatment of nabpaclitaxel plus gemcitabine, with overall survival identified as the primary endpoint. The biopharmaceutical company said it administered the first dose under the trial on Dec. 30, 2025.